

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
	Application Number	10/658,394		
	Filing Date	09-26-2003		
	First Named Inventor	MAILLIET		
	Group Art Unit	1609		
	Examiner Name	JARRELL, Noble E.		
	Attorney Docket Number	ST99049G1 - US - DIV		
Sheet	1	of	4	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/N J/ ↓ ↓		2003/0013711		MAILLIET	01-16-2003	
		10/773,806		HITTINGER	02-06-2004	
		5,767,278		GAETA et al	06-16-1998	
		5,770,613		GAETA et al	06-23-1998	
		5,854,244		JARMAN et al	12-29-1998	
		5,863,936		GAETA et al	01-26-1999	
		6,150,360		DAEYAERT et al	11-21-2000	
		6,262,053 B1		UCKUN et al	07-17-2001	
		6,362,210 B1		HAUEL et al	03-26-2002	
		6,858,608		MAILLIET	02-22-2005	
		6,887,873		MAILLIET	05-03-2005	
		6,995,175		BOUCHARD	02-07-2006	
		7,179,816		MAILLIET	02-20-2007	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/N J/ ↓ ↓		CA	2 325 489		LEHR et al	09-30-1999		
		DE	198 12 879 A1		KIRSTEN et al	09-30-1999	*	
		DE	199 35 219 A1		HAUEL et al	02-01-2001		
		JP	11-60573		MASAYUKI et al	03-02-1999		
		JP	53-47439		SHIZUO et al	04-27-1978		
		JP	6-49062		KATSUTOSHI et al	02-22-1994		
		WO	01/07020 A2		HAUEL et al	02-01-2001		
		WO	01/19825 A1		DENNY et al	03-22-2001		
		WO	01/47897 A1		MORIARTY et al	07-05-2001		
		WO	93/20056		JARMAN et al	10-14-1993		

Examiner Signature	/Noble Jarrell/	Date Considered	07/23/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Abstract / Structure only: *

☒

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/658,394	
			Filing Date	09-26-2003	
			First Named Inventor	MAILLET	
			Group Art Unit	1609	
			Examiner Name	JARRELL, Noble E.	
Sheet	2	of	4	Attorney Docket Number	ST99049G1 - US - DIV

[illegible][illegible]

Examiner Signature	/Noble Jarrell/	Date Considered	07/23/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/658,394	
			Filing Date	09-26-2003	
			First Named Inventor	MAILLIET	
			Group Art Unit	1609	
			Examiner Name	JARRELL, Noble E.	
Sheet	3	of	4	Attorney Docket Number	ST99049G1 - US - DIV

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/N.J./		ATWELL et al, Potential Antitumor Agents. V. Bisquaternary Salts, J. Med. Chem., Vol. 10, July 1967, pp. 706-713	
		ATWELL et al, Potential Antitumor Agents. VI. Bisquaternary Salts, J. Med. Chem., Vol.11, March 1968, pp. 295-300	
		CAIN et al, Potential Antitumor Agents. X. Bisquaternary Salts, J. Med. Chem., Vol. 12, No. 2, March 1969, pp. 199-206	
		CHEN et al, Spectroscopic Recognition of Guanine Dimeric Hairpin Quadruplexes by a Carbocyanine Dye, Proc. Natl. Acad. Sci. USA, Vol. 93, pp.2635-2639, April 1996	
		DENNY et al, Potential Antitumor Agents, 29. Quantitative Structure-Activity Relationships for the Antileukemic Bisquaternary Ammonium Heterocycles, J. Med. Chem., 1979, Vol. 22, No. 2, pp. 134-150	
		HIRATANI et al, 2,6-Bis[N-(8-quinolyl)carbamoyl]pyridine as a Highly Selective Extractant for Cu(II), Bulletin of The Chemical Society of Japan, 1990, 63, pp. 3331-3333	
		KATSUTOSHI et al, Pyrimidinylamino-or Triazinylaminoquinoline Derivative and Its Production and Agricultural and Horticultural Germicide Containing the Same as Active Ingredient, Patent Abstracts of Japan, Publication No. 06049062 A, Publication Date Feb. 22, 1994	
		KITTLER et al, Sequence Specific Modulation on DNA Restriction Enzyme Cleavage By Minor Groove Binders, Biol. Chem., Vol. 379, pp. 519-525, April/May 1998	
		KREUTZBERGER et al, Synthesis And Spectroscopic Analyses Of Dianilnotriazines, English Language Abstract of Chemiker-Zeitung (1990, pp.208-210, volume 114)	
↓		KREUTZBERGER, ET AL, Synthesis And Spectroscopic Analyses Of Dianilnotriazines, Chemiker-Zeitung (1990, pp.208-210, volume 114)	

Examiner Signature	/Noble Jarrell/	Date Considered	07/23/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/658,394
		Filing Date	09-26-2003
		First Named Inventor	MAILLIET
		Group Art Unit	1609
		Examiner Name	JARRELL, Noble E.
		Attorney Docket Number	ST99049G1 - US - DIV
Sheet	4	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
N.J./		MASAYUKI et al, Triazine Derivative and Telomerase Inhibitor, English Language Abstract of JP11-60573	
		MOKBEL et al, Telomerase and Breast Cancer: From Diagnosis to Therapy, Abstract of Int. J. Sug. Investig. 2000, 2(1), pp. 85-88	
		PANDYA et al, Studies on Potential Drugs : Potential Anthelmintics Part I, J. Inst. Chemists (India), Vol. XLVII, November 1975 pp. 235-237	
		SHIZUO et al, Coloring of High Molecular Weight Material, English Language Abstract of JP 53-47439	
		SUN et al, Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound, J. Med. Chem., 1997, 40, pp. 2113-2116	
		SWELLAM et al, Emerging role of p53, bcl-2 and Telomerase Activity in Egyptian Breast Cancer Patients, Abstract of IUBMB Life, 2004, 56(8), 483-490	
		WHEELHOUSE et al, Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA, J. Am. Chem. Soc., 1998, 120, pp. 3261-3262	
		WHITTEN et al, Rapid Microscale Synthesis, a New method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1 Receptor Antagonists, J. Med. Chem., 1996, 39, pp. 4354-4357	
✓		Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, Volume 1, 1004-1010, 1996	

Examiner Signature	/Noble Jarrell/	Date Considered	07/23/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.